Providence Saint-Joseph Medical Center

Burbank, California 91505-4866

2 studies enrolling now · 25 studies all time

What they study most

Acute Myocardial Infarction, Adenocarcinoma of the Colon, Atherosclerosis, B-cell Lymphoma, Breast Cancer, Cancer, Cardiovascular Diseases, Caregivers, Central Line Associated Blood Stream Infections (CLABSI), Cerebrovascular Accident, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Coronary Disease

Studies at this site

• A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 — Recruiting now
• Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction — Recruiting now
• Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer — Completed
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 — Running, not enrolling
• Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer — Completed
• Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI) — Completed
• Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma — Stopped early
• An Exploratory Study of Caregiver Burden Among Family Caregivers of Patients With Cancer — Completed
• Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma — Completed
• Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma — Completed
• BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab — Stopped early
• Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET — Completed
• VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer — Completed
• Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma — Completed
• Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer — Status unconfirmed
• Niacin Plus Statin to Prevent Vascular Events — Stopped early
• PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score — Completed
• Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer — Stopped early
• Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP) — Completed
• Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma — Completed
• Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma — Completed
• TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer — Completed
• A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas — Stopped early
• Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma — Completed
• Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Completed